Abstract:Over the past two decades, many pre-clinical and clinical studies have been conducted to establish stem cell therapy as a potential treatment for heart failure. Although the original purpose was to replace the scar lesion with new cardiomyocytes generated from stem cells, there is growing evidence that therapeutic benefits may be derived mostly from cardioprotective paracrine factors released by stem cells. Paracrine factors from several cell sources, including bone marrow-derived cells, endothelial cells, and mesenchymal stromal cells, have been shown to stimulate growth of new blood vessels and activate the endogenous repair pathway in the myocardium. Several studies hypothesized that these paracrine effects work through extracellular vesicles (EVs) secreted from stem cells. EVs, including exosomes and microvesicles, are released by different types of cells and involved in both physiological and pathophysiological processes. EVs are believed to mediate intercellular communication by transmitting information from the cells of origin to their target cells. Thus, attempts are being made to utilize EVs as novel tools for various therapeutic approaches such as antitumour and regenerative therapies, and some antitumour EVs have already entered phase II human clinical trials. Since the discovery of human induced pluripotent stem cells (iPSCs) by Shinya Yamanaka et al., they are increasingly being used in cardiovascular research for disease modelling, drug screening, personalized medicine, and regenerative medicine. Although previous studies have shown that transplantation of either human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or iPSC-derived cardiomyocytes (iPSC-CMs) to non-human primates can engraft or improve cardiac function through direct cardiomyocyte replacement, there are still several hurdles to overcome, including short-term ventricular arrythmias and long-term sustainable engraftment. In this issue of the journal, El Harane et al. sought to test whether EVs secreted by iPSC-derived cardiovascular progenitors (iPSC-PGs) can recapitulate the therapeutic effects of direct transplantation of iPSC-PGs. They successfully isolated EVs from iPSC-PGs, and found that iPSC-CMs did not produce EVs althogh the mechanism is unclear. EVs were internalized in vitro to target cells, which improved cell survival and proliferation of cultured H9C2 cardiomyocytes, and promoted angiogenesis including scratch wound healing and tube formation. Similarly, in vivo EV injection improved cardiac function in a murine myocardial infarction model. Surprisingly, the injection of EVs outperformed transplantation of their parent progenitor cells. The EVs were enriched with 16 highly conserved microRNAs (miRNAs), which are associated with biological functions expected to ameliorate heart failure. In terms of target genes of the miRNAs, they showed that the hearts from the three groups treated with iPSC-CMs, iPSCPGs, and EVs showed distict gene expression patterns. The work by El Harane et al. highlights the effect of EVs secreted by iPSC-PGs on chronic heart failure following myocardial infarction. In terms of clinical application, these results have three important implications. First, the source of EVs is progenitor cells differentiated from iPSCs, which are more available than hESCs from the ethical point of view. Second, the EV therapy is considered to be relatively safe because it is a cell-free therapy. Third, EV therapy was more effective in improving cardiac function in vivo than the direct transplantation of parent stem cells. In their previous studies, Kervadec et al. showed that the injection of EVs secreted from human embryonic stem cell-derived cardiovascular progenitor cells (hESC-PGs) could provide beneficial effects equivalent to those of cell transplantation therapy of parent hESCPGs in the treatment of chronic heart failure in mice.. While EV

Extracellular vesicles produced by human-induced pluripotent stem cell-derived endothelial cells can prevent arterial stenosis in mice via autophagy regulation

Exosomes Derived From Human Induced Pluripotent Stem Cells-Endothelia Cells Promotes Postnatal Angiogenesis In Mice Bearing Ischemic Limbs

Induced Pluripotent Stem Cells As a Biopharmaceutical Factory for Extracellular Vesicles

Exosomes/microvesicles from Induced Pluripotent Stem Cells Deliver Cardioprotective Mirnas and Prevent Cardiomyocyte Apoptosis in the Ischemic Myocardium

Extracellular vesicles derived from endothelial progenitor cells modified by Houshiheisan promote angiogenesis and attenuate cerebral ischemic injury via miR-126/PIK3R2

Extracellular vesicles from human embryonic stem cell-derived cardiovascular progenitor cells promote cardiac infarct healing through reducing cardiomyocyte death and promoting angiogenesis

Induced pluripotent stem cells attenuate chronic allogeneic vasculopathy in an integrin beta-1-dependent manner

Extracellular Vesicles from Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells (Hipsc-Mscs) Protect Against Renal Ischemia/reperfusion Injury Via Delivering Specificity Protein (SP1) and Transcriptional Activating of Sphingosine Kinase 1 and Inhibiting Necroptosis

Small extracellular vesicles secreted by human iPSC-derived MSC enhance angiogenesis through inhibiting STAT3-dependent autophagy in ischemic stroke

Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles on Atherosclerosis-Induced Vascular Dysfunction and Its Key Molecular Players

Neuroprotective Effects of Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell Extracellular Vesicles in Ischemic Stroke Models

Exosomes secreted by endothelial cells derived from human induced pluripotent stem cells improve recovery from myocardial infarction in mice

Large extracellular vesicles from induced pluripotent stem cell-marrow stem cells enhance limb angiogenesis via ERK/MAPK

Induced pluripotent stem cell-derived extracellular vesicles promote wound repair in a diabetic mouse model via an anti-inflammatory immunomodulatory mechanism

Heparan Sulfate Proteoglycan-Mediated Internalization of Extracellular Vesicles Ameliorates Liver Fibrosis by Targeting Hepatic Stellate Cells

Platelet extracellular vesicles enhance the proangiogenic potential of adipose-derived stem cells in vivo and in vitro

Induced Pluripotent Stem Cell‐derived Extracellular Vesicles Promote Wound Repair in a Diabetic Mouse Model Via an Anti‐inflammatory Immunomodulatory Mechanism

Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI

Human-Induced Pluripotent Stem-Cell-Derived Smooth Muscle Cells Increase Angiogenesis to Treat Hindlimb Ischemia

212 HUMAN INDUCED PLURIPOTENT STEM CELLS DIFFERENTIATE INTO PURE POPULATIONS OF ENDOTHELIAL CELLS MEDIATED BY SET SIMILAR PROTEIN THROUGH VE-CADHERIN TRANSCRIPTIONAL ACTIVATION

Small Extracellular Vesicles Derived from Induced Pluripotent Stem Cells in the Treatment of Myocardial Injury